<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551122</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000572096</org_study_id>
    <secondary_id>USCTU-UR1002-GEM-TIP</secondary_id>
    <secondary_id>EU-20769</secondary_id>
    <secondary_id>EUDRACT-2004-004804-19</secondary_id>
    <nct_id>NCT00551122</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors</brief_title>
  <acronym>GemTIP</acronym>
  <official_title>Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and
      cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or
      die. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when
      given together with paclitaxel, ifosfamide, and cisplatin, and to see how well they work in
      treating patients with progressive or relapsed metastatic germ cell tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the maximum tolerated dose (MTD) of gemcitabine hydrochloride when
           administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with
           growth factor support (Gem-TIP) in patients with progressive or relapsed metastatic germ
           cell tumors.

        -  To compare the MTD of the Gem-TIP regimen with the MTD determined in a previous Medical
           Research Council study of TIP alone.

        -  To compare the degree of dose intensification achieved with Gem-TIP chemotherapy with
           that achieved in the prior study of TIP chemotherapy alone.

        -  To assess the dose of gemcitabine hydrochloride that can be delivered with the TIP
           regimen in these patients.

        -  To measure response rates and failure-free survival of patients treated with Gem-TIP
           alone.

        -  To assess the utility of PET scanning after Gem-TIP chemotherapy in these patients.

      OUTLINE: This is a multicenter, phase I dose-escalation study of gemcitabine hydrochloride
      followed by a phase II study.

        -  Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes and paclitaxel IV
           over 3 hours on day 1, cisplatin IV over 4 hours on days 1-5, and ifosfamide IV over 1
           hour on days 2-6. Patients also receive filgrastim or lenograstim (G-CSF) subcutaneously
           (SC) on days 7-18 or until blood counts recover OR pegfilgrastim SC once on day 6.
           Treatment repeats every 3 weeks for up to 4 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Phase II: An additional cohort of 14 patients is treated as in phase I at the MTD
           determined in phase I.

      After completion of study therapy, patients are followed periodically for up to 1 year and
      then at the investigator's discretion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure-free survival (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.
If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.
Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.
MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lenograstim</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel, gemcitabine, cisplatin, ifosfamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets the following criteria:

               -  Histologically confirmed extracranial primary germ cell cancer, seminoma, or
                  nonseminoma

                    -  Unresectable metastatic disease

                    -  No completely resected cancer

               -  Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin)
                  on sequential measurement or biopsy-proven unresectable germ cell cancer

          -  In first relapse after a single prior cisplatin-containing combination chemotherapy

               -  Patients with late relapse (i.e., &gt; 2 years post initial chemotherapy) should be
                  considered for surgery rather than chemotherapy, if technically feasible

          -  No patients with cerebral metastases alone

               -  Progressive cerebral and systemic disease may be considered for this study,
                  provided cranial irradiation is also considered as a component of care

        PATIENT CHARACTERISTICS:

          -  Medically and psychologically fit to receive this intensive chemotherapy schedule

          -  WBC &gt; 3.5 times 10^9/L

          -  Platelet count &gt; 130 times 10^9/L

          -  Glomerular filtration rate ≥ 50 mL/min (as determined by 24 hour creatinine clearance
             or nuclear medicine technique)

          -  Fertile patients must use effective contraception

          -  No other prior malignancy except successfully treated nonmelanoma skin cancer or
             superficial bladder cancer

          -  No prior allergic reactions to cisplatin or other platinum compounds

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Mead, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael H. Cullen, MD</last_name>
      <phone>0121-627-2444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Mead, MD</last_name>
      <phone>44-23-8079-8639</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A. Huddart, MD</last_name>
      <phone>44-20-8661-3457</phone>
      <email>robert.huddart@icr.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>testicular seminoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>recurrent extragonadal seminoma</keyword>
  <keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage IV extragonadal seminoma</keyword>
  <keyword>recurrent extragonadal germ cell tumor</keyword>
  <keyword>ovarian mixed germ cell tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

